Clinical Trials Browser

Irritable Bowel Syndrome × GSK3352589 × Endocrine × Clear all

NCT03154086 2019-08-09

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

Phase 1 Completed

68 enrolled 80 charts

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome